Abstract:Objective: Hemangiomas are the most common benign vascular tumors of infancy. Although most infantile hemangiomas (IHs) have the ability to involute spontaneously after initial proliferation and resolve without consequence, intervention is required in a subset of IHs, which develop complications resulting in ulceration, bleeding, or aesthetic deformity. The primary treatment for this subset of IHs is pharmacological intervention, and propranolol has become the new first-line treatment for complicated hemangiomas. Here, we evaluated the efficacy of propranolol on proliferation IH in a clinical cohort including 578 patients.Methods: We retrospectively reviewed a total of 578 IH patients who were treated with oral propranolol from January 2010 to December 2012. Responses to the propranolol treatment were graded as: excellent, good, poor, or no response. Based on the response to propranolol treatment (once daily at a dose of 1.0 mg/kg for patients younger than 2 months; twice daily at daily total dose of 2 mg/kg for patients older than 2 months), additional pharmacotherapies or surgery were used for IH patients for satisfactory clinical outcome.Results: Five hundred and sixty (96.9%) of 578 IH patients in our study responded to oral propranolol treatment, and the response rate was significantly different for different ages of patients (P<0.05), with the youngest patients having the highest response rate. The mean time of treatment was 6 months (range, 3-12 months). For example, response rate to propranolol was 98.1% in patients younger than 2 months, compared with 93.3% in patients older than 2 months and younger than 8 months, and 73.7% in patients older than 8 months. One hundred and thirty one patients who exhibited incompletely involuted hemangiomas were further treated with timolol maleate (n=89) or pulsed dye laser (n=42). One hundred and seventeen (89.3%) of 131 patients showed a positive response. There were no instances of life-threatening complications after propranolol. However, minor side effects were observed including 10 (1.73%) cases of sleep disturbance, 7 (1.21%) cases of diarrhea, and 5 (0.86%) cases of bronchospasm.Conclusion: IH requires early intervention. During the involution phase, tapering propranolol dosage can be done to minimize side effects before discontinuing treatment. For patients exhibiting telangiectasia and chromatosis after propranolol treatment, administration of a 0.5% solution of timolol maleate or pulse dye laser is an effective therapeutic approach for complete involution.

Combination of Propranolol and Sclerotherapy for Treatment of Infantile Parotid Hemangiomas.

Use of Propranolol for Parotid Hemangioma

The Long-term Research of Propranolol Treatment for Giant Parotid Infantile Hemangomas

Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies

Preliminary Experiences in Treating Infantile Hemangioma with Propranolol

The efficacy of oral propranolol for infantile hemangiomas in 68 cases

Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study

Propranolol in the treatment of problematic infantile hemangiomas

Treatment of infantile hemangiomas with low-dose propranolol: evaluation of short-term efficacy and safety]

Comparison of Oral Propranolol Alone and Combined with Topical 0.5 ％ Timolol Maleate Cream for the Treatment of Infantile Hemangiomas

Is Propranolol Safe and Effective for Outpatient Use for Infantile Hemangioma? A Prospective Study of 679 Cases From One Center in China.

Clinical efficacy of oral propranolol for the treatment of infant proliferating hemangiomas and the changes of serum VEGF

[Oral Propranolol in the Management of Periorbital Proliferating Phase Infantile Hemangioma].

Effectiveness And Safety Of Oral Propranolol Versus Other Treatments For Infantile Hemangiomas: A Meta-Analysis

Evaluation on efficacy of different doses of propranolol in treatment of infantile hemangioma

Diagnosis of Infantile Subglottic Hemangioma and the Effect of Oral Propranolol.

Analysis of Factors Affecting the Therapeutic Effect of Propranolol for Infantile Haemangioma of the Head and Neck

Clinical evaluation of propranolol treatment for 53 infantile hemangiomas

Clinical Observations on Infantile Hemangiomas Treated with Low-Dose Propranolol

Microultrasound in Monitoring the Evolution of Infantile Hemangioma after Propranolol Treatment

Propranolol Therapy for Infantile Hemangioma: Our Experience